Objective:To explore the clinical effect of Fugan Xiaoji decoction and entecavir in the treatment of CHB cirrhosis with liver stagnation and spleen deficiency syndrome.Methods:A total of 60 patients with liver depression and spleen deficiency syndrome of CHB cirrhosis from January 2019 to January 2023 who were admitted in Guangchang County Traditional Chinese Medicine Hospital were selected.They were randomly divided into the study group(30 cases,Fugan Xiaoji decoction and entecavir)and the control group(30 cases,entecavir).Clinical efficacy was analyzed,and liver function,liver fibrosis indicators,and LSM were compared in both groups.Results:In the total effective rate of treatment,in comparision of the control group,the study group was higher(P＜0.05).After treatment,ALT,AST,and TBil levels in both groups were decreased(P＜0.05),A/G was increased(P＜0.05),and in comparision of the control group,ALT,AST,and TBil levels in the study group was lower(P＜0.05),and A/G was higher(P＜0.05).After treatment,HA,LN,C Ⅳ,and PC Ⅲ levels in both groups were decreased(P＜0.05),and in comparision of the control group,the study group was lower(P＜0.05).After treatment,LSM in both groups were decreased(P＜0.05),and in comparision of the control group,the study group was lower(P＜0.05).Conclusion:The combination of Fugan Xiaoji decoction and entecavir can improve clinical efficacy,liver function,liver fibrosis indicators,and liver hardness in the treatment of patients with liver depression and spleen deficiency syndrome in CHB cirrhosis.
Fugan Xiaoji decoctionEntecavirChronic hepatitis BLiver cirrhosisLiver depression and spleen deficiency syndromeClinical effects
NETL
NSTL
万方数据
